1/10/2012 6:26:37 AM
LEXINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Hydra Biosciences, Inc. today announced plans to begin a Phase 1 clinical trial for a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 (TRPA1) ion channel discovered in a collaboration between Cubist and Hydra. This Phase 1 trial is the first step in a clinical development program designed to evaluate the potential of this TRPA1 investigational product to treat acute pain and certain inflammatory conditions. Under the collaboration, the companies recently identified and completed preclinical testing on a potent, selective TRPA1 antagonist, CB-625 (full name CB-189,625), and filed for regulatory approval to initiate human clinical studies. The open-label, dose-escalation study to assess the safety and pharmacokinetics of CB-625 in healthy volunteers will be conducted in the Netherlands and is expected to start in the first quarter of 2012.
comments powered by